JLJ. Rebecca Liu

J. Rebecca Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


J. Rebecca Liu has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Lijun Tan

    Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, Michigan

    5 shared publications
  • Anthony W. Opipari

    Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, Michigan

    3 shared publications
  • Heather Wahl

    Department of Obstetrics and Gynecology, University of Michigan Health System, Ann Arbor, Michigan

    2 shared publications
  • Malti Kshirsagar

    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

    2 shared publications
  • Abhishek Shukla

    Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

    1 shared publication
  • Aine Clements

    OhioHealth Physician Group in Columbus, OH, United States of America

    1 shared publication

Latest Publications

  • Top Cited Papers

    Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258

    by Aine Clements, Danielle Enserro, Kyle C. Strickland, Rebecca Previs, Daniela Matei, David Mutch, Matthew Powell, Ann Klopp, David Scott Miller, William Small, et al.


  • Resveratrol inhibits ovarian tumor growth in an in vivo mouse model

    by Lijun Tan, Weimin Wang, Gong He, Rork D. Kuick, Gabrielle Gossner, Angela S. Kueck, Heather Wahl, Anthony W. Opipari, J. Rebecca Liu

    BACKGROUND: Resveratrol inhibits the growth of ovarian carcinoma cells in vitro through the inhibition of glucose metabolism and the induction of both autophagy and apoptosis. In the current study, we investigated the metabolic and therapeutic effects of resveratrol in vivo.METHODS: A fluorescent xenograft mouse model of ovarian cancer was used. Mice were treated with cisplatin, resveratrol, or vehicle alone. Tumor burden was assessed using whole‐body imaging. The effect of resveratrol on glucose uptake in vivo was determined using micro‐positron emission tomography scanning. To determine whether resveratrol could inhibit tumor regrowth, tumor‐bearing mice were treated with cisplatin followed by either daily resveratrol or vehicle. Autophagic response in resected tumors taken from mice treated with resveratrol was examined by transmission electron microscopy. Glycolysis and mitochondrial respiration in ovarian tumor cells after treatment with resveratrol was assessed.RESULTS: Mice treated with resveratrol and cisplatin were found to have a significantly reduced tumor burden compared with control animals (P<.001). Resveratrol‐treated mice demonstrated a marked decrease in tumor uptake of glucose compared with controls. After treatment with cisplatin, “maintenance” resveratrol resulted in the suppression of tumor regrowth compared with mice receiving vehicle alone (P<.01). Tumors resected from mice treated with resveratrol exhibited autophagosomes consistent with the induction of autophagy. Treatment with resveratrol inhibited glycolytic response in ovarian tumor cells with high baseline glycolytic rates.CONCLUSIONS: Treatment with resveratrol inhibits glucose uptake and has a significant antineoplastic effect in a preclinical mouse model of ovarian cancer. Resveratrol treatment suppresses tumor regrowth after therapy with cisplatin, suggesting that this agent has the potential to prolong disease‐free survival. Cancer 2016;122:722–729. © 2015 American Cancer Society.


  • Open Access

    Trichostatin A restores Apaf‐1 function in chemoresistant ovarian cancer cells

    by Lijun Tan, Roland P. Kwok, Abhishek Shukla, Malti Kshirsagar, Lili Zhao, Anthony W. Opipari, J. Rebecca Liu

    BACKGROUND: Chemoresistance is the major factor limiting long‐term treatment success in patients with epithelial ovarian cancers. Most cytotoxic drugs kill cells through apoptosis; therefore, defective execution of apoptotic pathways results in a drug‐resistant phenotype in many tumor types.METHODS: A panel of ovarian cancer cell lines was screened for expression and function of the apoptosome components Apaf‐1 and caspase‐9. Expression levels were analyzed by immunohistochemistry and immunoblotting; Apaf‐1 function was determined by assessing the ability of endogenous Apaf‐1 to cleave caspase‐9 in the presence or absence of cytochrome c. The effect of the histone deacetylase inhibitor trichostatin A on Apaf‐1 expression and function was evaluated.RESULTS: The authors report here that the resistance of ovarian cancer cells to the proapoptotic effects of chemotherapy is due in part to deficient Apaf‐1 activity. Although Apaf‐1 is expressed in most ovarian cancers, the functional activity is impaired, as Apaf‐1 has a diminished ability to recruit and activate caspase‐9. Treatment of ovarian cancer cells with trichostatin A results in restoration of Apaf‐1 function independent of alterations in Apaf‐1 expression. Furthermore, treating chemoresistant cells with sublethal doses of trichostatin A restores Apaf‐1 function and sensitizes cells to cisplatin‐induced apoptosis.CONCLUSIONS: Targeting intrinsic pathway defects for therapeutic intervention may result in sensitizing tumors to standard chemotherapy or triggering apoptosis in the absence of other apoptotic signals. The identification of drugs that can use Apaf‐1 when it is present, yet can overcome its functional inactivation, may be an important clinical advance. Cancer 2011. © 2010 American Cancer Society.


  • Expression of metabolically targeted biomarkers in endometrial carcinoma

    by Heather Wahl, Sayeema Daudi, Malti Kshirsagar, Kent Griffith, Lijun Tan, Jennifer Rhode, J. Rebecca Liu


  • Open Access

    Physician and patient attitudes towards complementary and alternative medicine in obstetrics and gynecology

    by Mandi L Furlow, Divya A Patel, Ananda Sen, J Rebecca Liu

    Background: In the U.S., complementary and alternative medicine (CAM) use is most prevalent among reproductive age, educated women. We sought to determine general attitudes and approaches to CAM among obstetric and gynecology patients and physicians. Methods: Obstetrician-gynecologist members of the American Medical Association in the state of Michigan and obstetric-gynecology patients at the University of Michigan were surveyed. Physician and patient attitudes and practices regarding CAM were characterized. Results: Surveys were obtained from 401 physicians and 483 patients. Physicians appeared to have a more positive attitude towards CAM as compared to patients, and most reported routinely endorsing, providing or referring patients for at least one CAM modality. The most commonly used CAM interventions by patients were divergent from those rated highest among physicians, and most patients did not consult with a health care provider prior to starting CAM. Conclusion: Although obstetrics/gynecology physicians and patients have a positive attitude towards CAM, physician and patients' view of the most effective CAM therapies were incongruent. Obstetrician/gynecologists should routinely ask their patients about their use of CAM with the goal of providing responsible, evidence-based advice to optimize patient care.


  • Open Access

    Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells

    by Jennifer Rhode, Sarah Fogoros, Suzanna Zick, Heather Wahl, Kent A Griffith, Jennifer Huang, J Rebecca Liu

    Background: Ginger (Zingiber officinaleRosc) is a natural dietary component with antioxidant and anticarcinogenic properties. The ginger component [6]-gingerol has been shown to exert anti-inflammatory effects through mediation of NF-κB. NF-κB can be constitutively activated in epithelial ovarian cancer cells and may contribute towards increased transcription and translation of angiogenic factors. In the present study, we investigated the effect of ginger on tumor cell growth and modulation of angiogenic factors in ovarian cancer cellsin vitro.Methods: The effect of ginger and the major ginger components on cell growth was determined in a panel of epithelial ovarian cancer cell lines. Activation of NF-κB and and production of VEGF and IL-8 was determined in the presence or absence of ginger.Results: Ginger treatment of cultured ovarian cancer cells induced profound growth inhibition in all cell lines tested. We found thatin vitro, 6-shogaol is the most active of the individual ginger components tested. Ginger treatment resulted in inhibition of NF-kB activation as well as diminished secretion of VEGF and IL-8.Conclusion: Ginger inhibits growth and modulates secretion of angiogenic factors in ovarian cancer cells. The use of dietary agents such as ginger may have potential in the treatment and prevention of ovarian cancer.


  • Placenta percreta following first trimester miscarriage

    by P.K. Brahma, R. Lieberman, C. Przybycin, J.R. Liu


  • Apoptosome dysfunction in human cancer

    by K. M. Hajra, J. R. Liu

    Apoptosis is a cell suicide mechanism that enables organisms to control cell number and eliminate cells that threaten survival. The apoptotic cascade can be triggered through two major pathways. Extracellular signals such as members of the tumor necrosis factor (TNF) family can activate the receptor-mediated extrinsic pathway. Alternatively, stress signals such as DNA damage, hypoxia, and loss of survival signals may trigger the mitochondrial intrinsic pathway. In the latter, mitochondrial damage results in cytochrome c release and formation of the apoptosome, a multimeric protein complex containing Apaf-1, cytochrome c, and caspase-9. Once bound to the apoptosome, caspase-9 is activated, and subsequently triggers a cascade of effector caspase activation and proteolysis, leading to apoptotic cell death. Recent efforts have led to the identification of multiple factors that modulate apoptosome formation and function. Alterations in the expression and/or function of these factors may contribute to the pathogenesis of cancer and resistance of tumor cells to chemotherapy or radiation. In this review we discuss how disruption of normal apoptosome formation and function may lead or contribute to tumor development and progression.


  • Resveratrol-induced Autophagocytosis in Ovarian Cancer Cells

    by Anthony W. Opipari, Lijun Tan, Anthony E. Boitano, Dorothy R. Sorenson, Anjili Aurora, J. Rebecca Liu

    Resveratrol (3,5,4-trihydroxystilbene), a natural phytoalexin present in grapes, nuts, and red wine, has antineoplastic activities. Several molecular mechanisms have been described to underlie its effects on cells in vitro and in vivo. In the present study, the response of ovarian cancer cells to resveratrol is explored. Resveratrol inhibited growth and induced death in a panel of five human ovarian carcinoma cell lines. The response was associated with mitochondrial release of cytochrome c, formation of the apoptosome complex, and caspase activation. Surprisingly, even with these molecular features of apoptosis, analysis of resveratrol-treated cells by light and electron microscopy revealed morphology and ultrastructural changes indicative of autophagocytic, rather than apoptotic, death. This suggests that resveratrol can induce cell death through two distinct pathways. Consistent with resveratrol’s ability to kill cells via nonapoptotic processes, cells transfected to express high levels of the antiapoptotic proteins Bcl-xL and Bcl-2 are equally sensitive as control cells to resveratrol. Together, these findings show that resveratrol induces cell death in ovarian cancer cells through a mechanism distinct from apoptosis, therefore suggesting that it may provide leverage to treat ovarian cancer that is chemoresistant on the basis of ineffective apoptosis.